USPTO trademark

BIOHAVEN PHARMACEUTICALS

RegisteredUSPTOWord and designClass 5Class 42

"BIOHAVEN PHARMACEUTICALS" is a word and design mark owned by Biohaven Therapeutics Ltd., filed at the USPTO on June 22, 2021. It is registered and covers classes 5 and 42.

View Biohaven Therapeutics Ltd. portfolioGet this data via the API
Official USPTO record
BIOHAVEN PHARMACEUTICALS trademark as filed
As filed with the USPTO
Status
Registered
Since January 25, 2022
Filed
June 22, 2021
Registered
January 25, 2022
Expires
Not recorded
Application no.
90788388
Registration no.
6629316
Office
USPTO
United States Patent and Trademark Office
Mark type
Word and design
2 classes
Ownership

Who owns BIOHAVEN PHARMACEUTICALS

The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.

Owner

Biohaven Therapeutics Ltd.

BHVN · Road Town, Tortola, British Virgin Islands

84 trademarks in the portfolioView company

Representative

Monica Riva Talley

Sterne, Kessler, Goldstein & Fox P.L.L.C.

Goods and services

What the mark covers

The products and services BIOHAVEN PHARMACEUTICALS is filed for, grouped by Nice class.

  • Medicated and pharmaceutical preparations, both prescription and over-the-counter, for use in connection with humans and animals, namely, for the treatment of central nervous system disorders, neurologic illnesses, and psychiatric illnesses; pharmaceutical preparations for the treatment of brain ischemia; pharmaceutical preparations for the treatment of brain ischemia, namely, post-stroke recovery, severe intracranial atherosclerosis, carotid endarterectomy, cardiac bypass, cerebral vasculitis, reversible cerebral vasoconstriction syndrome; pharmaceutical preparations for the treatment of brain and cord injuries; pharmaceutical preparations for the treatment of brain and cord injuries, namely, post- intracranial hemorrhage recovery, traumatic brain injury, spinal cord injury; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Huntington's disease, Lewy body dementia, frontotemporal dementia, vascular dementia, Parkinson's disease, cognitive impairment of aging, progressive Multiple Sclerosis; pharmaceutical preparations for the treatment of optic and retinal neuropathies; pharmaceutical preparations for the treatment of optic and retinal neuropathies, namely, glaucoma, diabetic retinopathy, ischemic optic and retinal neuropathies; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of pain, namely, opioid sparing analgesia, cancer pain, chronic neuropathic pain, peripheral neuropathy, low back pain in the nature of failed back surgery syndrome, radiculopathy in the nature of sciatica, diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy induced neuropathy and other medication induced neuropathies, complex regional pain syndrome, fibromyalgia, chronic post-operative pain, cluster thoracotomy, phantom limb, stump neuroma; pharmaceutical preparations for the treatment of headache and facial pain, namely, headache, migraine, chronic daily headache, cluster headache, trigeminal neuralgia; pharmaceutical preparations for symptomatic treatments of degenerative diseases; pharmaceutical preparations for symptomatic treatments of degenerative diseases, namely, breath holding in Rett syndrome, dystonias, dysphagia, gait abnormalities, bulbar function in Amyotrophic Lateral Sclerosis (ALS), pseudobulbar affect, levodopa-induced dyskinesias in Parkinson's disease, agitation in Alzheimer's disease (AD), disinhibition in dementia; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of epilepsy, namely, precision medicine for the adjuvant for genetic epilepsy due to NMDA receptor mutations with hyperactivation; pharmaceutical preparations for the treatment of neuropsychiatric disorders; pharmaceutical preparations for the treatment of neuropsychiatric disorders, namely, treatment resistant depression, Post Traumatic Stress Disorder (PTSD) in the nature of hyperarousal, substance abuse disorders, addiction disorders, Obsessive Compulsive Disorder (OCD), hoarding, trichotillomania, eating disorders, Generalized Anxiety Disorder (GAD), adjustment disorders, panic disorder, major depressive episode, bipolar disorder in the nature of manic and depressive episodes, dysthymia, cyclothymia, psychotic disorders, schizophrenia; pharmaceutical preparations for the treatment of cerebellar disorders; pharmaceutical preparations for the treatment of cerebellar disorders, namely, spinocerebellar ataxia, Friedriech's ataxia, multisystem atrophy, essential tremor; pharmaceutical preparations for the treatment of hearing disorders, tinnitus, delirium, sleep disorders, parasomnias, learning disorders, Attention Deficit Disorder (ADD), Pervasive Developmental Disorders (PDD), Asperger's syndrome, autism, menopausal hot flashes; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer, namely, monotherapy and adjunctive use

  • Pharmaceutical research and development in the fields of headache, facial pain, impulse control disorders, neurological disorders, and neurodegenerative disorders, and consultation provided in conjunction therewith

History

What has happened so far

Steps recorded by the USPTO, newest first.

  1. Applicant/correspondence changes (non-responsive) entered
  2. Teas change of correspondence received
  3. Attorney/dom.rep.revoked and/or appointed
  4. Teas revoke/app/change addr of atty/dom rep received
  5. Teas change of owner address received
  6. Assignment of ownership not updated automatically
  7. Registered-principal register
  8. Assignment of ownership not updated automatically
  9. Official gazette publication confirmation e-mailed
  10. Published for opposition

10 earlier steps on the official record.

Disputes

Oppositions and cancellations

Proceedings recorded against this mark by the USPTO. Reported as recorded, not legal advice.

FAQ

About BIOHAVEN PHARMACEUTICALS

Who owns the trademark "BIOHAVEN PHARMACEUTICALS"?

The USPTO trademark "BIOHAVEN PHARMACEUTICALS" (application 90788388) is owned by Biohaven Therapeutics Ltd.

What is the status of "BIOHAVEN PHARMACEUTICALS"?

Its status at the USPTO is: registered.

When was "BIOHAVEN PHARMACEUTICALS" registered?

It was registered on January 25, 2022.

API

Get this data via the API

Everything on this page comes from the Signa API. Pull BIOHAVEN PHARMACEUTICALS and marks like it into your own product with one request.

  • GET/v1/trademarks/{id}

    The full record: owners, classes, dates and images

  • GET/v1/trademarks/{id}/events

    Every step in the office history

  • GET/v1/proceedings?trademark_id={id}

    Oppositions and cancellations against the mark

Get API keyView docs
GET /v1/trademarks/{id}
ID=tm_019d2d73-bcca-769e-af91-a1dc25f6e49e
curl https://api.signa.so/v1/trademarks/$ID \
  -H "Authorization: Bearer $SIGNA_API_KEY"
Response
{
  "id": "tm_019d2d73-bcca-769e-af91-a1dc25f6e49e",
  "object": "trademark",
  "mark_text": "BIOHAVEN PHARMACEUTICALS",
  "status": {
    "primary": "active",
    "stage": "registered"
  },
  "office_code": "US",
  "application_number": "90788388",
  "filing_date": "2021-06-22",
  "nice_classes": [
    5,
    42
  ],
  "owners": [
    {
      "name": "Biohaven Therapeutics Ltd.",
      "entity_id": "ent_019eb7d2-fb5b-7654-8bb0-d58ab7c6ce1e"
    }
  ]
}